Timothy M. Ring Sells 269,661 Shares of Becton Dickinson and Co (BDX) Stock
Becton Dickinson and Co (NYSE:BDX) Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Becton Dickinson and Co (BDX) opened at $218.89 on Tuesday. Becton Dickinson and Co has a one year low of $175.66 and a one year high of $248.39. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $50,220.00, a PE ratio of 167.09, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm posted $2.33 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. equities research analysts expect that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.
BDX has been the topic of several recent research reports. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Argus increased their target price on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Bank of America reissued a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $237.27.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legacy Advisors LLC raised its position in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the period. Amica Retiree Medical Trust raised its position in shares of Becton Dickinson and by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the period. FTB Advisors Inc. raised its position in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the period. Advisors Preferred LLC acquired a new stake in shares of Becton Dickinson and during the fourth quarter worth about $126,000. Finally, Harfst & Associates Inc. raised its position in shares of Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the period. 75.56% of the stock is currently owned by institutional investors.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.